Episode summary
The Everything Pill | Barron's Streetwise
Barron's Streetwise
· · Hosts: Jack
Summary
GLP-1 obesity drugs are presented as one of Wall Street’s biggest growth stories, with Eli Lilly and Novo Nordisk positioned to benefit from rising insurance coverage, broader Medicare access and new oral versions of the medicines. The host argues the market is still early, but already large enough that Lilly’s profits and valuation look increasingly tied to a franchise that could expand well beyond weight loss.
The central investment case is that these drugs may become an “everything pill” class, not just obesity treatments. The host says they are being studied for sleep apnea, fatty liver, heart disease, addiction, kidney disease, Alzheimer’s, Parkinson’s, arthritis, psoriasis, asthma and even cancer risk reduction. An analyst from Morgan Stanley says estimates have risen to a $190 billion diabetes-and-obesity market by 2035, and that new indications could open additional adjacent markets not yet fully in consensus numbers.
The discussion also compares Lilly and Novo on efficacy, scale and patent risk. The analyst says Lilly’s injectable has the better clinical profile, while Novo’s pill currently has the lead in market share. Both speakers argue the patent cliff looks manageable because innovation, manufacturing complexity and new formulations can keep branded sales growing even as generics emerge.
Key takeaways
- The host says GLP-1s are now the second biggest profit-growth story on Wall Street after AI, led by Eli Lilly.
- Morgan Stanley’s analyst says US uptake is still in the early-to-middle innings, with roughly 30% year-over-year growth.
- The analyst raises the 2035 diabetes-and-obesity market estimate to $190 billion and says new indications are not fully reflected in current numbers.
- Lilly’s injectable is viewed as superior to Novo’s, while Novo’s pill has an early share lead but faces a scaling disadvantage.
- Patent-expiry risk is described as manageable because branded innovation and manufacturing barriers may preserve premium pricing.
Notable quotes
“I think we're still in the early to middle innings here of uptake of these medicines”
“the growth has been very robust. I think what we're seeing now is kind of 30% year-over-year in the US”
“we do expect Lily to catch up over the course of the year”
How the episode opens
If these drugs are successful at showing benefits in brain diseases, mental health conditions, or inflammatory conditions, that could open additional adjacent markets. That's something that's not fully reflected in our numbers or consensus numbers. Hello and welcome to the Baron Street Wise podcast.
I'm Jack How and the voice you just heard, that's Terrence Flynn. He's the head of US pharma and biotech at Morgan Stanley and he's talking about obesity drugs or GLP1s we go v zepbound that sort of thing. I will argue in a moment that this business has become the biggest profit story on Wall Street short of artificial intelligence and there are new breakthroughs on the horizon in weight loss drugs and also some patent pitfalls to be aware of but they look manageable.
Let's get into it. Listening in is our audio producer Emily Sumland. Hi Emily.
Hi Jack.
I wrote a cover story this past week for Baron's magazine on what I called the everything drug. I'll explain that in a moment. This is a subject that I've written about for years.
We've had Eli Liy CEO Dave Ricks on the podcast before. There's a column I wrote for Barons about four years ago on this subject where I confessed to weighing an eighth of a ton. Emily, I don't want you to be too alarmed.
That's 250 lbs.
Don't worry, Jack. I can't run those numbers in my head. It was a real mystery to me. — Two 250. I looked it up. That's a pretty healthy weight for a harbor seal or a panda, but not so much for a human male, even one who's 6'4. The good news is, and Emily, here's where you're really going to be impressed. I think I'm down a little over 10 pounds since then.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- glp-1 drugs
- pharmaceutical growth
- obesity drugs
- drug class innovation
- healthcare market
Watch the episode
Watch “The Everything Pill | Barron's Streetwise” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Barron's Streetwise
-
America’s Debt Reckoning: 5 Paths Forward | Barron's Streetwise -
AI’s Big Payoff? Apollo’s Top Economist Doesn’t See It Yet. -
Does Show Business Still Work? | Barron's Streetwise -
The Disruption Scorecard | Barron's Streetwise -
Spooky Agents, Cable’s Second Death, and Stock Picks | Barron's Streetwise -
Buybacks, Bond Doubts, DRAM, and T-Rex | Barron's Streetwise
Barron's Streetwise, this episode and its artwork belong to Barron's. Octagon is not affiliated with the show; this page is an independent summary.
